CliffBio
small molecule

PERSERIS KIT

RISPERIDONE

Loss of exclusivityFebruary 2028latest FDA-listed patent expiry
CompanyIndivior →See this company's full patent-cliff portfolio

Drug detail

Brand namePERSERIS KIT
Active ingredientRISPERIDONE
Strength120MG
Dosage formFOR SUSPENSION, EXTENDED RELEASE
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalJuly 2018
Marketing statusDISCN

Listed patents

PatentExpiresType
9180197February 2028product
11712475February 2028use U-3135
11013809February 2028product
9186413February 2028use U-543
10010612February 2028product
10376590February 2028use U-2608
11110093November 2026product
9597402September 2026product
10058554September 2026use U-2363
10406160June 2026product

More from Indivior

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

PERSERIS KIT patent cliff — loss of exclusivity February 2028 | CliffBio